

Every Breath Matters

Don't let RSV take your baby's breath away

Pfizer's ABRYSVO[®] is the only RSV vaccine given while pregnant to help protect newborns from severe RSV from birth through 6 months.

 **ABRYSVO[®]**
Respiratory Syncytial Virus Vaccine

from

 **Pfizer**

RSV (Respiratory Syncytial Virus)

WHAT IS ABRYSVO?

ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

SELECTED IMPORTANT SAFETY INFORMATION

- ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
- An increased risk of Guillain-Barré syndrome (severe muscle weakness) was observed after vaccination with ABRYSVO

Please see Important Safety Information on pages 2-5.
Please click [here](#) for full [Prescribing Information](#) for ABRYSVO.

RSV puts your baby at risk

RSV is a highly contagious respiratory virus that can affect your child, especially during their first 6 months of life.

The virus can impact the lungs and airways, potentially making it difficult for an infant to breathe. Just like the flu, RSV can range from mild to severe.

75^{to}80%

of RSV hospitalizations occur during the first 6 months of life.

Nearly

50%


of RSV hospitalizations occur during the first three months of life.

IMPORTANT SAFETY INFORMATION

- ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
- An increased risk of Guillain-Barré syndrome (severe muscle weakness) was observed after vaccination with ABRYSVO

Please see additional Important Safety Information on pages 3-5.
Please click [here](#) for full Prescribing Information for ABRYSVO.

Your child is susceptible to RSV immediately after birth

A close-up photograph of a woman with dark hair, smiling warmly at a newborn baby. The baby is lying in a hospital bed, looking towards the woman with its mouth open as if crying or calling out. The woman is wearing a green hospital gown. The background is softly blurred, showing a hospital setting.

The CDC recommends a single dose of ABRYSVO be given to pregnant women at 32 through 36 weeks gestation during September through January (in most of the United States). In some states, the recommended months for maternal vaccination may differ. Start a conversation with your doctor to learn more.

IMPORTANT SAFETY INFORMATION (CONTINUED)

- To avoid the potential risk of preterm birth, ABRYSVO should be given during 32 through 36 weeks gestational age
- Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
- Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO

Please see additional **Important Safety Information** on pages 2-5.
Please click [here](#) for full **Prescribing Information** for ABRYSVO.

Protect your baby against RSV with Pfizer's ABRYSVO, the only maternal vaccine for RSV




Scan this QR code or visit abrysv.com/maternal-rsv-vaccine-planner. Using your due date and location, you can check your eligibility for ABRYSVO.

Getting recommended vaccinations are an important part of prenatal care

Since 2005, pregnant women have been receiving the Tdap vaccine to help protect their babies from whooping cough.

Pfizer's ABRYSVO works similarly to the Tdap vaccine, helping your body create antibodies that are passed to your unborn baby. By getting vaccinated with ABRYSVO, you can help protect your child against RSV from their first breath through 6 months.



IMPORTANT SAFETY INFORMATION (CONTINUED)

- Vaccination with ABRYSVO may not protect all people
- In pregnant individuals, the most common side effects ($\geq 10\%$) were pain at the injection site, headache, muscle pain, and nausea
- In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

Please see additional Important Safety Information on pages 2-5.
Please click [here](#) for full Prescribing Information for ABRYSVO.

Getting vaccinated helps protect your baby against RSV during their first RSV season

Talk to your OB to learn more about ABRYSVO.



Scan with your smartphone camera to see where you can get ABRYSVO near you.



IMPORTANT SAFETY INFORMATION (CONTINUED)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <http://www.vaers.hhs.gov> or call 1-800-822-7967.

Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791. The registry will monitor pregnancy outcomes.

Please see additional Important Safety Information on pages 2-4.
Please click here for full [Prescribing Information](#) for ABRYSVO.



Cost and coverage*

Pfizer's ABRYSSVO may be made available by certain insurance plans at no cost in accordance with the Inflation Reduction Act.*

Talk to your doctor or pharmacist to see if Pfizer's ABRYSSVO is covered under your insurance plan. Additional savings and support options may be available at [Pfizer RxPathways](#)®.

*This information is provided for informational purposes only. Accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. Pfizer and its agents make no guarantee regarding reimbursement for any service or item. Certain vaccines may be covered or available at lower out-of-pocket costs in Medicare Part D, Medicaid, the Children's Health Insurance Program, or other consumer plans through the Inflation Reduction Act. Coverage may vary based on the vaccine and the insurance plan. For more information, visit [cms.gov](https://www.cms.gov).



 **ABRYSSVO**®
Respiratory Syncytial Virus Vaccine

from



Please see Important Safety Information on pages 2-5.
Please click for full [Prescribing Information](#) for ABRYSSVO.